[Pomalidomide for multiple myeloma].

[1]  Mahmoud S. Assaf,et al.  Pomalidomide: Evaluation of cytochrome P450 and transporter‐mediated drug–drug interaction potential in vitro and in healthy subjects , 2015, Journal of clinical pharmacology.

[2]  K. Anderson,et al.  Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. , 2014, Blood.

[3]  G. Morgan,et al.  Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma , 2014, Leukemia.

[4]  Christopher J. Ott,et al.  The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins , 2014, Science.

[5]  S. Lonial,et al.  MM-008: A Phase 1 Trial Evaluating Pharmacokinetics and Tolerability Of Pomalidomide + Low-Dose Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment , 2013 .

[6]  H. Goldschmidt,et al.  Final Analysis, Cytogenetics, Long-Term Treatment, and Long-Term Survival In MM-003, A Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM) , 2013 .

[7]  B. Pégourié,et al.  Pomalidomide Plus Low-Dose Dexamethasone In Relapsed Or Refractory Multiple Myeloma (RRMM) With Deletion (del)17p and/Or Translocation t(4;14) , 2013 .

[8]  A. Dispenzieri,et al.  Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma , 2013, Blood Cancer Journal.

[9]  C. Hofmeister,et al.  Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis. , 2013 .

[10]  B. Pégourié,et al.  Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. , 2013, Blood.

[11]  N. Munshi,et al.  Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. , 2013, Blood.

[12]  H. Goldschmidt,et al.  Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study , 2012, Leukemia.

[13]  D. Dingli,et al.  Improved survival in multiple myeloma and the impact of novel therapies. , 2008, Blood.

[14]  R. Kyle,et al.  Epidemiology of the plasma-cell disorders. , 2007, Best practice & research. Clinical haematology.